27 results
Thumbnail

- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells

Thumbnail

- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study

Thumbnail

- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib

Thumbnail

- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series

Thumbnail

- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis

Thumbnail

D3.213 - Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study

Thumbnail

D3.198 - Challenges of using clinical scores as primary endpoints in allergology trials

Thumbnail

D3.199 - Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy

Thumbnail

D3.200 - Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure

Thumbnail

D3.201 - Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents

Thumbnail

D3.202 - Characterising relevant major allergens beyond modification: from allergen to allergoid

Thumbnail

D3.203 - Characterisation of relevant allergens in grass pollen extracts

Thumbnail

D3.205 - Two-year Outcomes of Multiple Low-Dose Oral Immunotherapies for combination of Tree Nuts or Peanut for Severe Allergy Patients

Thumbnail

D3.206 - Pollen-Food Allergy Syndrome (PFAS): A New Paradigm in Allergy Practice – Results of a Survey Among Allergists

Thumbnail

D3.207 - Symptomatology and Sensitization Profiles of Patients Undergoing Subcutaneous Immunotherapy for Aeroallergens in Greece

Thumbnail

D3.208 - Security of initiation of SCIT in the day hospital

Thumbnail

D3.209 - Subcutaneous Allergen Immunotherapy in Children: Frequency of Local and Systemic Adverse Reactions and Associated Risk Factors

Thumbnail

D3.214 - A multi-epitope protein promotes regulatory T-cell responses in PBLs from HDM-allergic patients

Thumbnail

- D3.519 - Post-COVID-19 Reshaping of Molecular IgE Sensitization Profiles to Seasonal and Indoor Allergens

Thumbnail

- D3.520 - Post-COVID Olfactory and Taste Dysfunction in Students at a South African Medical School